Read by QxMD icon Read

NAFLD fibrosis score

Beatriz A Sánchez-Jiménez, Diana Brizuela-Alcántara, Martha H Ramos-Ostos, Luis F Alva-López, Misael Uribe-Esquivel, Norberto C Chávez-Tapia
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. Mortality in NAFLD is mainly related to cardiovascular disease (CVD) and cancer. NAFLD and its association with both CVD and liver disease risk have been well evaluated, but the association of NAFLD with alcohol, known as "both alcoholic and non-alcoholic steatohepatitis" (BASH), remains uncertain. The objective of this study was to assess the influence of alcohol and obesity in the development of liver and cardiovascular disease risk...
November 15, 2017: Alcohol
Chang-Hoon Lee, Seung Ho Choi, Goh Eun Chung, Boram Park, Min-Sun Kwak
BACKGROUND/AIMS: The association between nonalcoholic fatty liver disease (NAFLD) and lung function has not been fully examined. The aim of this study is to clarify the association between NAFLD and lung function in general population by performing cross-sectional and longitudinal analysis. METHODS: Participants without hepatic and respiratory disease who underwent regular health exams including hepatic sonography and spirometry with at least 3 years' follow-up were included...
April 16, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Ying Peng, Yan Li, Yonghong He, Qinglin Wei, Qiaoling Xie, Liangjun Zhang, Yiju Xia, Xueqian Zhou, Lu Zhang, Xinchan Feng, Kun Chen, Sheng Chen, Wensheng Chen, Qinglin Long, Jin Chai
Neutrophil to lymphocyte ratio (NLR) is widely used to assess inflammatory diseases. We performed a systematic review to explore the prognostic role of NLR for the assessment of liver fibrosis and cirrhosis. Areas covered: We searched the PubMed and EMBASE databases for the eligible papers which explored the association between NLR and liver fibrosis/cirrhosis or investigated the prognostic value of NLR in cirrhotic patients. Expert commentary: In accordance with assessment of liver fibrosis stage, we classified papers into four subgroups by etiology...
April 9, 2018: Expert Review of Gastroenterology & Hepatology
Edoardo G Giannini, Claudia Coppo, Chiara Romana, Giovanni B Camerini, Franco De Cian, Nicola Scopinaro, Francesco S Papadia
BACKGROUND: Obesity is associated with NAFLD, and bariatric surgery has significant impact on this liver disease, with reported improvement in hepatic fibrosis. AIMS: To investigate the effects of bariatric surgery on long-term liver disease-related outcome in obese patients with nonalcoholic fatty liver disease (NAFLD) and significant liver damage. METHODS: This study included 56 NAFLD patients who underwent bilio-pancreatic diversion for morbid obesity and who had significant fibrosis at intraoperative liver biopsy...
April 9, 2018: Digestive Diseases and Sciences
Asuman Celikbilek, Mehmet Celikbilek, Gurbet Bozkurt
OBJECTIVE: The aim of this study was to investigate cognitive performance for the first time in participants with nonalcoholic fatty liver disease (NAFLD) using the Montreal Cognitive Assessment (MoCA). PARTICIPANTS AND METHODS: In total, 70 participants with NAFLD and 73 age-matched and sex-matched healthy participants were enrolled in this prospective cross-sectional study. The diagnosis of NAFLD was made on the basis of abdominal ultrasonography findings. Anthropometric indices were calculated, and routine laboratory analyses were carried out for each participant...
March 31, 2018: European Journal of Gastroenterology & Hepatology
Pegah Golabi, Maria Stepanova, Huong T Pham, Rebecca Cable, Nila Rafiq, Haley Bush, Trevor Gogoll, Zobair M Younossi
Background: Hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) independently predicts mortality. Given liver biopsy's invasive nature, non-invasive method to assess hepatic steatosis and fibrosis provides NAFLD risk stratification algorithm in clinical practice. NAFLD fibrosis score (NFS) is simple and non-invasive predictive model recommended by American Association for the Study of Liver Disease (AASLD) Guideline to identify patients with NAFLD with fibrosis risk...
2018: BMJ Open Gastroenterology
Goh Eun Chung, Jeong-Hoon Lee, Heesun Lee, Min Kyung Kim, Jeong Yoon Yim, Su-Yeon Choi, Yoon Jun Kim, Jung-Hwan Yoon, Donghee Kim
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) may be associated with a wide spectrum of cardiac abnormalities, which share many metabolic risk factors. This study aimed to evaluate whether NAFLD is associated with left ventricular (LV) diastolic dysfunction independent of other classical risk factors. METHODS: A total of 3300 subjects (mean age, 54.1 years; 62.9% men), who underwent echocardiography and hepatic ultrasonography, were enrolled. LV diastolic dysfunction was diagnosed and graded using conventional and Doppler echocardiographic assessments...
March 17, 2018: Atherosclerosis
Joshua A Welsh, Eleonora Scorletti, Geraldine F Clough, Nicola A Englyst, Christopher D Byrne
The enhanced liver fibrosis (LFS) score and the nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) are algorithmic-derived scores for diagnosing severe (F3/F4) liver fibrosis. In a pilot, substudy of the Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy (WELCOME) trial, we tested whether measurements of plasma platelet-, endothelial-, and leukocyte-derived extracellular vesicles (EVs) counts are (a) associated with, and predict, F3/F4 fibrosis and (b) able to improve risk prediction of F3/F4 fibrosis in NAFLD, building upon LFS or NFS algorithms...
March 30, 2018: Journal of Leukocyte Biology
Anna Di Sessa, Giuseppina Rosaria Umano, Grazia Cirillo, Angela Del Prete, Roberta Iacomino, Pierluigi Marzuillo, Emanuele Miraglia Del Giudice
BACKGROUND: The rs641738 polymorphism in the membrane-bound O-acyltransferase domain containing protein 7 (MBOAT7) gene has been associated with increased risk of nonalcoholic fatty liver disease (NAFLD). OBJECTIVES: To investigate the association between the MBOAT7 rs641738 polymorphism and both hepatic steatosis and biochemical markers of liver damage and to evaluate the potential additive effect of this variant and the I148M patatin-like phospholipase domain-containing 3 (PNPLA3) and the rs58542926 transmembrane 6 superfamily member 2 (TM6SF2) polymorphisms...
March 29, 2018: Journal of Pediatric Gastroenterology and Nutrition
Sampath De Silva, Wenhao Li, Polychronis Kemos, James H Brindley, Jibran Mecci, Salma Samsuddin, Joanne Chin-Aleong, Roger M Feakins, Graham R Foster, Wing-Kin Syn, William Alazawi
Objective: Liver biopsy is the most accurate method for determining stage and grade of injury in non-alcoholic fatty liver disease (NAFLD). Given risks and limitations of biopsy, non-invasive tests such as NAFLD fibrosis score, aspartate transaminase (AST) to platelet ratio index, Fib-4, AST/alanine transaminase ratio and BARD are used. Prevalence and severity of NAFLD and metabolic syndrome vary by ethnicity, yet tests have been developed in largely white populations. We tested our hypothesis that non-invasive tests that include metabolic parameters are less accurate in South Asian compared with white patients...
April 2018: Frontline Gastroenterology
J Boursier, R Anty, L Vonghia, V Moal, T Vanwolleghem, C M Canivet, S Michalak, S Bonnafous, P Michielsen, F Oberti, A Iannelli, L Van Gaal, S Patouraux, O Blanchet, A Verrijken, P Gual, M-C Rousselet, A Driessen, G Hunault, S Bertrais, A Tran, P Calès, S Francque
BACKGROUND: The composite histological endpoint comprising nonalcoholic steatohepatitis (NASH) and NAFLD activity score ≥4 and advanced fibrosis (F ≥ 2) ("fibrotic NASH") is becoming an important diagnostic target in NAFLD: it is currently used to select patients for inclusion in phase III therapeutic trials and will ultimately be used to indicate treatment in clinical practice once the new drugs are approved. AIM: To develop a new blood test specifically dedicated for this new diagnostic target of interest...
March 25, 2018: Alimentary Pharmacology & Therapeutics
Luis C Bertot, Gary P Jeffrey, Bastiaan de Boer, Gerry MacQuillan, George Garas, Justin Chin, Yi Huang, Leon A Adams
BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) patients with diabetes are at increased risk of cirrhosis and liver-related death, and thus accurate fibrosis assessment in these patients is important. We examined the ability of non-invasive fibrosis models to determine cirrhosis and outcomes in NAFLD patients with and without diabetes. METHODS: NAFLD patients diagnosed between 2006-2015 had Hepascore, NAFLD fibrosis score (NFS), APRI and FIB-4 scores calculated at baseline and were followed for outcomes of overall and liver-related mortality/liver transplantation, hepatic decompensation and hepatocellular carcinoma (HCC)...
March 25, 2018: Liver International: Official Journal of the International Association for the Study of the Liver
Helena Katchman, Shira Zelber-Sagi, Aharon Baruch, Galia Berman, Idit F Schwartz, Doron Schwartz, Richard Nakache, Yaacov Goykhman, Polina Katz, Oren Shibolet, Moshe Shashar, Ayelet Grupper
BACKGROUND: There is growing evidence linking nonalcoholic fatty liver disease (NAFLD) with reduced Glomerular Filtration Rate (GFR). Living kidney donors do not have underlying kidney disease, but have reduced GFR as a result of nephrectomy. Whether kidney donation is associated with a higher risk for development or progression of NAFLD is currently unknown. METHODS: Retrospective evaluation of metabolic parameters and sonographic evidence of NAFLD was performed in 232 living kidney donors and 162 healthy controls...
March 25, 2018: Clinical Transplantation
Naoyuki Fujimori, Takeji Umemura, Takefumi Kimura, Naoki Tanaka, Ayumi Sugiura, Tomoo Yamazaki, Satoru Joshita, Michiharu Komatsu, Yoko Usami, Kenji Sano, Koji Igarashi, Akihiro Matsumoto, Eiji Tanaka
AIM: To examine the relationship between serum autotaxin (ATX) concentrations and clinicopathological findings in non-alcoholic fatty liver disease (NAFLD) patients. METHODS: One hundred eighty-six NAFLD patients who had undergone liver biopsy between 2008 and 2017 were retrospectively enrolled. Serum samples were collected at the time of biopsy and ATX was measured by enzyme immunoassays. Sera obtained from 160 healthy, non-obese individuals were used as controls...
March 21, 2018: World Journal of Gastroenterology: WJG
Jayanta Paul, Raj Vigna Venugopal, Lorance Peter, Kula Naresh Kumar Shetty, Mohit P Shetti
BACKGROUND: Liver biopsy is a gold standard method for hepatic steatosis assessment. However, liver biopsy is an invasive and painful procedure and can cause severe complications therefore it cannot be frequently used in case of follow-up of patients. Non-invasive assessment of steatosis and fibrosis is of growing relevance in non-alcoholic fatty liver disease (NAFLD). To evaluate hepatic steatosis, transient elastography with controlled attenuation parameter (CAP) measurement is an option now days...
January 2018: Arquivos de Gastroenterologia
Hye Ryoun Jang, Danbee Kang, Dong Hyun Sinn, Seonhye Gu, Soo Jin Cho, Jung Eun Lee, Wooseong Huh, Seung Woon Paik, Seungho Ryu, Yoosoo Chang, Tariq Shafi, Mariana Lazo, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
This study aimed to investigate the association of nonalcoholic fatty liver disease (NAFLD) and its severity with the decline in kidney function in patients with chronic kidney disease (CKD). We conducted a cohort study of 1,525 CKD patients who underwent repeated health check-up examinations from January 2003 through December 2013. NAFLD was diagnosed by ultrasonography and its severity was assessed by the NAFLD fibrosis score. At baseline, the prevalence of NAFLD was 40.9%, and the mean estimated glomerular filtration rate (eGFR) was 59...
March 16, 2018: Scientific Reports
Ivy N Haskins, Julietta Chang, Zubaidah Nor Hanipah, Tavankit Singh, Neal Mehta, Arthur J McCullough, Stacy A Brethauer, Philip R Schauer, Ali Aminian
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) increases the risk of liver cirrhosis and hepatocellular carcinoma and is also strongly correlated with extrahepatic diseases, including cardiovascular disease and type 2 diabetes. This risk of NAFLD among obese individuals who are otherwise metabolically healthy is not well characterized. OBJECTIVES: To determine the prevalence and characteristics of NAFLD in individuals with metabolically healthy obesity. SETTING: A tertiary, academic, referral hospital...
March 2018: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
Jihane N Benhammou, Tien S Dong, Folasade P May, Jenna Kawamoto, Ram Dixit, Samuel Jackson, Vivek Dixit, Debika Bhattacharya, Steven B Han, Joseph R Pisegna
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct-acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response 12 weeks (SVR12) after completion of therapy. Historically, African-Americans have had lower SVR12 rates compared to White people in the interferon era, which had been attributed to the high prevalence of non-CC interleukin 28B (IL28B) type. Less is known about the association between race/ethnicity and SVR12 in DAA-treated era...
April 2018: Pharmacology Research & Perspectives
Hirofumi Fukushima, Shunhei Yamashina, Atsushi Arakawa, Gentaro Taniguchi, Tomonori Aoyama, Akira Uchiyama, Kazuyoshi Kon, Kenichi Ikejima, Sumio Watanabe
BACKGROUND: Hepatic inclusion composed of autophagy-specific substrate p62 is one of the histological features of non-alcoholic fatty liver disease (NAFLD) and can be a precursor to hepatic carcinogenesis. The expression of p62 was enhanced by not only autophagic dysfunction but also oxidative stress and inflammation. M1/M2 phenotypic balance of macrophages plays a pivotal role in the progression of NAFLD. We evaluated the correlation between macrophage-polarization and the formation of p62 aggregation in NAFLD...
February 26, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
Rocío Aller de la Fuente, Natalia Mora Cuadrado, Carla Tafur, Juan Jose López Gómez, Sara Gómez de la Cuesta, María Concepción García Sánchez, Beatriz Antolin Melero, Daniel Antonio de Luis Román
BACKGROUND AND AIMS: Prevalence of non-alcoholic fatty liver disease (NAFLD) in developed countries is 30% in the general population and 50% in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to compare the severity of NAFLD, as assessed by liver biopsy and using the non-invasive index NAFLD Fibrosis Score (NFS), in subjects with and without T2DM. PATIENTS AND METHODS: The study sample consisted of 217 patients with biopsy-proven NAFLD. Anthropometric assessments, laboratory tests, histological criteria established by the Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN), and the NFS were recorded...
February 21, 2018: Endocrinología, Diabetes y Nutrición
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"